Adial Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on April 12, 2024. The company seeks to have the registration become effective on April 19, 2024, at 5:00 p.m. Eastern Time, or as soon as possible thereafter. This request was communicated in a letter to the SEC, highlighting the company's acknowledgment of its obligations under federal securities laws regarding the issuance of securities covered by the statement. Adial Pharmaceuticals has designated Leslie Marlow and Hank Gracin of Blank Rome LLP with the authority to modify or withdraw the acceleration request if necessary.

Adial Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on April 12, 2024. The company seeks to have the registration become effective on April 19, 2024, at 5:00 p.m. Eastern Time, or as soon as possible thereafter. This request was communicated in a letter to the SEC, highlighting the company's acknowledgment of its obligations under federal securities laws regarding the issuance of securities covered by the statement. Adial Pharmaceuticals has designated Leslie Marlow and Hank Gracin of Blank Rome LLP with the authority to modify or withdraw the acceleration request if necessary.